Ge Jingjing, Lei Yaxin, Wen Qing, Zhang Yue, Kong Xiaoshuang, Wang Wenhua, Qian Siyu, Hou Huting, Wang ZeYuan, Wu Shaoxuan, Dong Meng, Ding Mengjie, Wu Xiaolong, Feng Xiaoyan, Zhu Linan, Zhang Mingzhi, Chen Qingjiang, Zhang Xudong
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Nutr. 2022 Oct 5;9:981338. doi: 10.3389/fnut.2022.981338. eCollection 2022.
The prognostic nutritional index (PNI) is an important prognostic factor for survival outcomes in various hematological malignancies. The current study focused on exploring the predictive value of the PNI in newly diagnosed follicular lymphoma (FL) in China.
The clinical indicators and follow-up data of 176 patients who received chemotherapy or immunotherapy combined with chemotherapy with FL in our hospital from January 2016 to March 2022 were retrospectively analyzed. Cox proportional hazard model was used for univariate and multivariate analyses. Kaplan-Meier curves were used to calculate survival rates and draw survival curves. The log-rank test was applied to compare differences between groups.
The optimal cut-off value of PNI was 44.3. All patients were divided into a high PNI group (>44.3) and a low PNI group (≤44.3). The low PNI group had a low CR rate and a high risk of death, with a tendency toward POD24, and Both OS and PFS were worse than those in the high PNI group. PNI was able to predict OS and PFS in FL patients and was the only independent predictor of OS ( = HR 5.024; 95%CI 1.388∼18.178) in multivariate analysis. PNI could re-stratify patients into groups of high FLIPI score, high FLIPI2 score, no POD24, and rituximab combined with chemotherapy. Moreover, integrating PNI into the FLIPI and FLIPI2 models improved the area under the curve (AUC) for more accurate survival prediction and prognosis.
PNI is a significant prognostic indicator for newly diagnosed FL in China that can early identify patients with poor prognosis and guide clinical treatment decisions.
预后营养指数(PNI)是多种血液系统恶性肿瘤生存结局的重要预后因素。本研究聚焦于探索PNI在中国新诊断滤泡性淋巴瘤(FL)中的预测价值。
回顾性分析2016年1月至2022年3月在我院接受化疗或免疫治疗联合化疗的176例FL患者的临床指标和随访数据。采用Cox比例风险模型进行单因素和多因素分析。使用Kaplan-Meier曲线计算生存率并绘制生存曲线。应用对数秩检验比较组间差异。
PNI的最佳截断值为44.3。所有患者分为高PNI组(>44.3)和低PNI组(≤44.3)。低PNI组的完全缓解率低且死亡风险高,有发生24个月无进展生存(POD24)的趋势,总生存期(OS)和无进展生存期(PFS)均比高PNI组差。PNI能够预测FL患者的OS和PFS,并且在多因素分析中是OS的唯一独立预测因子(风险比[HR]=5.024;95%置信区间[CI]为1.388~18.178)。PNI可将患者重新分层为高滤泡性淋巴瘤国际预后指数(FLIPI)评分、高FLIPI2评分、无POD24以及利妥昔单抗联合化疗组。此外,将PNI纳入FLIPI和FLIPI2模型可提高曲线下面积(AUC),以更准确地预测生存和预后。
PNI是中国新诊断FL的重要预后指标,可早期识别预后不良患者并指导临床治疗决策。